Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iCROSS: Neoadjuvant Tislelizumab + Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
NCT04973306Phase 3Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Started Mar 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04973306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973306.